Intended Use: For In Vitro Diagnostic Use Smooth Muscle Myosin Heavy Chain [SMMS-1] is a mouse monoclonal antibody that is intended for laboratory use in the qualitative identification of both isoforms of the human smooth muscle myosin heavy chain (SM1 and SM2) structural proteins by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues. The clinical interpretation of any staining or its absence should be complemented by morphological studies using proper controls and should be evaluated within the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.
Summary and Explanation:
Smooth Muscle-Myosin Heavy Chain (SM-MHC) is a cytoplasmic structural protein that is a major component of the contractile apparatus in smooth muscle cells. Expression of smooth muscle myosin is developmentally regulated, appearing early and is specific for smooth muscle development. SM-MHC stains the intact myoepithelial cell (MEC) layers present in benign and in situ malignant breast and bronchioloalveolar lesions and is therefore very helpful in distinguishing between benign and malignant tumors. Studies have shown that Calponin, SM-MHC and p63 labeled MECs in intraductal and micropapillary DCIS cases while invasive papillary carcinomas (IC) were uniformly negative for all cases. Staining with p63 was discontinuous, making interpretation difficult. Calponin was more sensitive and intense than SM-MHC but less specific exhibiting crossreactivity with myofibroblastic cells. Although CD10 can aid in the distinction between IC and DCIS, SM-MHC is a more sensitive and specific marker of MEC and shows less heterogeneity of immunostaining pattern. SM-MHC also reacts with visceral and vascular smooth muscle cells.
Principle of Procedure:
Antigen detection in tissues and cells is a multi-step immunohistochemical process. The initial step binds the primary antibody to its specific epitope. After labeling the antigen with a primary antibody, a secondary antibody is added to bind to the primary antibody. An enzyme label is then added to bind to the secondary antibody; this detection of the bound antibody is evidenced by a colorimetric reaction. 
Limitations:
The optimum antibody dilution and protocols for a specific application can vary. These include, but are not limited to fixation, heat-retrieval method, incubation times, tissue section thickness and detection kit used. Due to the superior sensitivity of these unique reagents, the recommended incubation times and titers listed are not applicable to other detection systems, as results may vary. The data sheet recommendations and protocols are based on exclusive use of Biocare products. Ultimately, it is the responsibility of the investigator to determine optimal conditions. The clinical interpretation of any positive or negative staining should be evaluated within the context of clinical presentation, morphology and other histopathological criteria by a qualified pathologist. The clinical interpretation of any positive or negative staining should be complemented by morphological studies using proper positive and negative internal and external controls as well as other diagnostic tests. (6) 2. Specimens, before and after fixation, and all materials exposed to them should be handled as if capable of transmitting infection and disposed of with proper precautions. Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents or specimens come in contact with sensitive areas, wash with copious amounts of water. (7) 3. Microbial contamination of reagents may result in an increase in nonspecific staining.
Catalog Number:
CM 420 A, B PM 420 AA Description: 0.1, 0.5 ml, concentrated 6.0 ml, prediluted
Dilution:
1:100 Ready-to-use
Diluent:
Renoir Red N/A
